Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 22nd International Myeloma Society (IMS) Annual Meeting was held in Toronto, Canada, from September 17-20, 2025. This meeting brought together leading experts as they discussed the latest clinical and experimental advances in multiple myeloma.
View all videos

IMS 2025

The 22nd International Myeloma Society Annual Meeting
17–20 September 2025 | Toronto, Canada

IMS 2025

The 22nd International Myeloma Society Annual Meeting
17–20 September 2025 | Toronto, Canada
The 22nd International Myeloma Society (IMS) Annual Meeting was held in Toronto, Canada, from September 17-20, 2025. This meeting brought together leading experts as they discussed the latest clinical and experimental advances in multiple myeloma.
View all videos

Latest Videos

View all videos
2:37
A national cancer nurse education needs assessment in the UK on bispecific antibody therapy
Chantelle Hughes • 20 Sep 2025
1:49
Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ?
Francesco Maura • 19 Sep 2025
2:01
Genomic drivers of resistance to anti-BCMA immunotherapies in multiple myeloma
Francesco Maura • 19 Sep 2025
1:55
Optimizing the dose of belamaf in transplant-ineligible NDMM: insights from the DREAMM-9 trial
Karthik Ramasamy • 15 Sep 2025

Trial Updates

View all
1:55
Optimizing the dose of belamaf in transplant-ineligible NDMM: insights from the DREAMM-9 trial
Karthik Ramasamy • 15 Sep 2025
3:19
Quadruplet regimens in transplant-ineligible NDMM: the new standard of care
Xavier Leleu • 17 Sep 2025

Immuno-Oncology

View all
2:37
A national cancer nurse education needs assessment in the UK on bispecific antibody therapy
Chantelle Hughes • 20 Sep 2025
1:49
Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ?
Francesco Maura • 19 Sep 2025

MRD

View all
4:12
PRO and safety in patients with NDMM achieving MRD negativity in the PERSEUS and CEPHEUS trials
Jesús San Miguel • 9 Sep 2025
2:17
Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma
Noemí Puig • 18 Sep 2025

Disease Biology

View all
1:49
Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ?
Francesco Maura • 19 Sep 2025
2:01
Genomic drivers of resistance to anti-BCMA immunotherapies in multiple myeloma
Francesco Maura • 19 Sep 2025
The content of VJHemOnc is intended for healthcare professionals